Newsfiscal.ai
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab
· Published
Article summary
Oculis Holding AG has successfully completed patient randomization for its PREDICT-1 registrational clinical trial evaluating licaminlimab for the treatment of TNFR1-mediated dry eye disease.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…